News

Business Wire2y
Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors ...
Business Wire8mon
Nate Hardy to Join Arsenal Biosciences, Inc. as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for ...
Yahoo Finance8mon
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs Through Clinical Development
SOUTH SAN FRANCISCO, Calif., September 04, 2024--(BUSINESS WIRE)--Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T ...
Yahoo Finance4mon
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T cell ...
pharmaphorum5d
Roche puts $70m into ArsenalBio's programmable T-cell platform
Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform. Genentech is ...
FierceBiotech8mon
ArsenalBio raises $325M for solid tumor CAR-T science with Regeneron and BMS in tow
Arsenal Biosciences is moving on up. The cell therapy company has added on $325 million in ammunition with big-name backers like Regeneron joining the artillery as the biotech sets out to build ...
Investing4mon
Assembly Biosciences extends lease through 2029
Assembly Biosciences extends lease through 2029 ...
Investing4mon
Assembly Biosciences extends lease through 2029
On Monday, Assembly Biosciences (NASDAQ: ASMB), Inc., a biopharmaceutical company with a market capitalization of $111.7 million, announced an extension of its sublease for office and laboratory ...